A DRD2 polymorphism predicts PANSS score variability in schizophrenia patients treated with antipsychotics
Data(s) |
30/05/2010
|
---|---|
Resumo |
Antipsychotic medications act as either antagonists or partial agonists of the dopamine D2 receptor (DRD2) and antipsychotic drugs vary widely in their binding affinity for the D2 receptor (Kapur and Seeman, 2000). The DRD2 957CNT (rs6277) polymorphism has previously been associated with schizophrenia (Lawford et al., 2005) and the T-allele of the 957CNT polymorphism is associated with reduced mRNA stability and synthesis of the dopamine D2 receptor (Duan et al., 2003). The aim of the study was to determine if the rs6277 polymorphism predicts some of the variability of positive and negative symptoms observed in schizophrenia patients being treated with antipsychotic medication. |
Formato |
application/pdf |
Identificador | |
Publicador |
Elsevier |
Relação |
http://eprints.qut.edu.au/40589/1/40589.pdf DOI:10.1016/j.psychres.2010.02.015 Voisey, Joanne, Swagell, Christopher D., Hughes, Ian P., Barnes, Mark, Burton, Simon C., van Daal, Angela M., Morris, C. Phillip, Lawford, Bruce R., & Young, Ross McD. (2010) A DRD2 polymorphism predicts PANSS score variability in schizophrenia patients treated with antipsychotics. Psychiatry Research, 177(3), pp. 367-368. |
Direitos |
Copyright © 2010 Elsevier Ltd All rights reserved. |
Fonte |
Cell & Molecular Biosciences; Faculty of Health; Faculty of Science and Technology; Institute of Health and Biomedical Innovation; School of Psychology & Counselling |
Palavras-Chave | #060410 Neurogenetics #110300 CLINICAL SCIENCES #111714 Mental Health #170200 COGNITIVE SCIENCE #Dopamine #Genotype #Psychological Disorder #Medication #Genetics |
Tipo |
Journal Article |